Same-day dispatch
Order before 2pm ET — ships from Toronto
COA in every box
Batch-matched third-party certificate
Cold-pack shipped
Temperature-controlled packaging
Purity guarantee
Below spec? Replaced or refunded
Tirzepatide
The Dual GLP-1/GIP Agonist — Zepbound's Active Research Compound
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly, marketed as Mounjaro (diabetes) and Zepbound (obesity). Zepbound generated USD $4.9 billion in its first full year of sales (2024), and the full tirzepatide portfolio (Mounjaro) reached $23.9 billion in global 2024 sales. Phase 3 SURMOUNT trials demonstrated up to 22.5% mean body weight reduction at 72 weeks. The North America GLP-1 market is projected to reach $38.8 billion by 2030.
- Dual GIP and GLP-1 receptor agonist — the current benchmark comparator
- SURMOUNT-1 reported 20.9% mean body-weight reduction at 72 weeks
- Batch-verified 98.3% HPLC purity with COA included
Vial size
10mg per vial · Lyophilized Powder · Ships same business day from Toronto
Questions about this batch? Text an agent at (905) 993-4764
20.9%
Mean weight reduction
SURMOUNT-1, 72 weeks, 15mg weekly
2.30%
HbA1c reduction
SURPASS program, highest-dose arm
2
Receptor targets
GIP + GLP-1 dual agonism
Research benefits
Dual Receptor Agonism
Simultaneously activates GIP and GLP-1 receptors for additive metabolic effects in research models
SURMOUNT Trial Data
Up to 22.5% mean body weight reduction at 72 weeks (Phase 3, NEJM 2022)
Insulin & Fat Research
Studied for superior effects on insulin resistance, fat mass reduction, and lipid profiles vs. GLP-1 alone
Study findings
Summaries of published research on this compound. Findings are reported for scientific context only and do not constitute claims about this product.
SURMOUNT-1 — obesity
Mean percentage change in body weight at 72 weeks was -20.9% with 15mg tirzepatide versus -3.1% with placebo in 2,539 participants.
New England Journal of Medicine · 2022
SURPASS-2 — versus semaglutide
Tirzepatide produced greater HbA1c and body-weight reductions than semaglutide 1mg across all dose arms.
New England Journal of Medicine · 2021
GIP receptor contribution
Dual incretin agonism improved insulin sensitivity and adipose-tissue handling beyond GLP-1 agonism alone in mechanistic studies.
Cell Metabolism · 2021
What researchers report
Aggregated, anonymized observations from laboratories ordering this compound. Anecdotal and non-clinical.
Most commonly ordered as the active comparator against semaglutide in head-to-head research designs.
Researchers consistently report clean, fully soluble reconstitution with no visible particulates.
Repeat purchase rate on this SKU is among the highest in the metabolic category.
Technical specifications
| Form | Lyophilized Powder |
| Sequence | Dual GIP / GLP-1 receptor agonist |
| Molecular Weight | 4813.45 g/mol |
| Purity | ≥99% |
| Amount | 10mg per vial |
| Storage | Store at -20°C, protect from light |
| Shelf Life | 24 months (stored at -20°C) |
| COA | COA Available → View Lab Results |
Storage & reconstitution
Store lyophilized vial at -20°C, protected from light.
Reconstitute slowly with bacteriostatic water; avoid foaming.
Refrigerate at 2–8°C and use within 30 days.
Research background
Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist, designed to activate two complementary incretin pathways with a single molecule.
Phase 3 SURMOUNT trials (NEJM 2022) demonstrated mean body weight reductions of up to 22.5% at 72 weeks.
The compound has rapidly become one of the most commercially significant peptides in history, with the broader portfolio reaching $23.9B globally in 2024.
Frequently stacked with
Semaglutide
GLP-1 receptor agonist for metabolic and weight research.
COA AvailableAvailable in 5mg · 10mg · 20mg
Retatrutide
Triple GLP-1/GIP/Glucagon agonist — next-gen metabolic research.
COA AvailableAvailable in 5mg · 10mg · 20mg · 40mg
Third-party verified
ISO 17025 accredited lab — Batch TR-TIRZ-2026-001
HPLC Purity
98.3%
Molecular Weight
✓ Verified
Endotoxin (LAL)
<1.0 EU/mg
Heavy Metals (ICP-MS)
✓ Pass
Tirzepatide — frequently asked
How is tirzepatide different from semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide targets GLP-1 only. Head-to-head trials reported larger reductions with tirzepatide.
What does SURMOUNT-1 show?
A mean 20.9% body-weight reduction at 72 weeks in the 15mg arm versus 3.1% for placebo.
Is a COA included?
Yes — a batch-matched third-party COA ships with every order.
How fast does it ship?
Orders placed before 2pm ET ship the same business day from Toronto with tracked Canada-wide delivery, typically arriving in 1–3 business days. Cold-pack packaging is used on every shipment.
What if the purity doesn't match the COA?
Every batch is HPLC and mass-spec verified by an ISO 17025 accredited third-party lab, and the batch-matched COA ships with your order. If an independent test comes back below the stated purity, we replace the order or refund it in full.
Is this legal to purchase in Canada?
Yes — these compounds are sold strictly as in-vitro research chemicals for laboratory use. They are not for human or veterinary use, and it is the purchaser's responsibility to comply with applicable federal and provincial regulations.
Ready to add Tirzepatide to your research?
≥99% HPLC-verified, endotoxin and heavy metals tested, batch-matched COA included. Ships same business day from Toronto.
Research Use Only Disclaimer
This product is sold exclusively for in-vitro research and laboratory use only. It is NOT intended for human or veterinary use, consumption, injection, or any clinical application. This product has not been evaluated by Health Canada, the FDA, or any other regulatory authority for safety or efficacy in humans or animals. Trinity makes no medical claims regarding this compound. Researchers must comply with all applicable federal, provincial/state, and local laws regarding the purchase, storage, and use of research compounds. By purchasing this product, you confirm you are a qualified researcher or licensed professional acting within the bounds of applicable law.